A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection.

Andreakos, Evangelos;Abel, Laurent;Vinh, Donald C;Kaja, Elżbieta;Constantinescu, Stefan;et.al.
(2022) Nature immunology — Vol. 23, n° 2, p. 159-164 (2022)

Files

2022_Andreakos_Nature_Immun.pdf
  • Open Access
  • Adobe PDF
  • 1019.02 KB

Details

Authors
  • Andreakos, Evangelosorcid-logo
    Author
  • Abel, Laurent
    Author
  • Vinh, Donald Corcid-logo
    Author
  • Kaja, Elżbietaorcid-logo
    Author
  • Collaborator
Show more
Abstract
SARS-CoV-2 infections display tremendous interindividual variability, ranging from asymptomatic infections to life-threatening disease. Inborn errors of, and autoantibodies directed against, type I interferons (IFNs) account for about 20% of critical COVID-19 cases among SARS-CoV-2-infected individuals. By contrast, the genetic and immunological determinants of resistance to infection per se remain unknown. Following the discovery that autosomal recessive deficiency in the DARC chemokine receptor confers resistance to Plasmodium vivax, autosomal recessive deficiencies of chemokine receptor 5 (CCR5) and the enzyme FUT2 were shown to underlie resistance to HIV-1 and noroviruses, respectively. Along the same lines, we propose a strategy for identifying, recruiting, and genetically analyzing individuals who are naturally resistant to SARS-CoV-2 infection.
Affiliations

Citations

Andreakos, E., Abel, L., Vinh, D. C., Kaja, E., Drolet, B. A., Zhang, Q., O’Farrelly, C., Novelli, G., Rodríguez-Gallego, C., Haerynck, F., Prando, C., Pujol, A., Su, H. C., Casanova, J.-L., & Spaan, A. N. (2022). A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection. Nature immunology, 23(2), 159-164. https://doi.org/10.1038/s41590-021-01030-z (Original work published 2022)